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Abstract
Background: Joint modeling of longitudinal and survival data has been increasingly considered in clinical trials,
notably in cancer and AIDS. In critically ill patients admitted to an intensive care unit (ICU), such models also
appear to be of interest in the investigation of the effect of treatment on severity scores due to the likely
association between the longitudinal score and the dropout process, either caused by deaths or live discharges
from the ICU. However, in this competing risk setting, only cause-specific hazard sub-models for the multiple failure
types data have been used.
Methods: We propose a joint model that consists of a linear mixed effects submodel for the longitudinal
outcome, and a proportional subdistribution hazards submodel for the competing risks survival data, linked
together by latent random effects. We use Markov chain Monte Carlo technique of Gibbs sampling to estimate the
joint posterior distribution of the unknown parameters of the model. The proposed method is studied and
compared to joint model with cause-specific hazards submodel in simulations and applied to a data set that
consisted of repeated measurements of severity score and time of discharge and death for 1,401 ICU patients.
Results: Time by treatment interaction was observed on the evolution of the mean SOFA score when ignoring
potentially informative dropouts due to ICU deaths and live discharges from the ICU. In contrast, this was no
longer significant when modeling the cause-specific hazards of informative dropouts. Such a time by treatment
interaction persisted together with an evidence of treatment effect on the hazard of death when modeling
dropout processes through the use of the Fine and Gray model for sub-distribution hazards.
Conclusions: In the joint modeling of competing risks with longitudinal response, differences in the handling of
competing risk outcomes appear to translate into the estimated difference in treatment effect on the longitudinal
outcome. Such a modeling strategy should be carefully defined prior to analysis.
Background
When evaluating the efficacy of a new drug through
randomized clinical trials (RCT) in critically ill patients,
the primary endpoint of interest is usually death from
any cause within some fixed period, generally 28 or 90
days after randomization. However, to better investigate
the effect of treatment, one is often interested in evalu-
ating how a biomarker of interest changes over time
and how this change may be correlated with the
treatment under study; this defines secondary endpoints
of interest.
In critically ill patients, the measure of treatment
effectiveness is based on the severity of the illness and
degree of organ failure, determined using severity scores
such as the APACHE (acute physiology and chronic
health evaluation) II score [1] or the Glasgow coma
score [2] and the SOFA (sequential organ failure assess-
ment) score [3], respectively. However, while the two
former scores are mostly used at entry to risk-stratify
patients by severity of illness, the latter also applies to
quantify evolution of the patient’s severity of illness and
even benchmark intensive care unit performance [4].
Furthermore, beyond reporting a better record of the
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impact of new treatments on patient outcome [5].
However, to evaluate whether treatment administra-
tion influences the course of organ failure, statistical
analysis is often based on naive comparisons across ran-
domized groups over time [6-8]. Mixed-effects models,
which incorporate repeated measurements of SOFA
over time in the same patients, appear to be a well
established method for studying the relationship
between treatment and the SOFA course. However,
given the strong association between organ dysfunction
and mortality for critically ill patients, the occurrence of
death could result in non-trivial missing data for the
longitudinal process. This is likely to provide biased
results [9-12].
In a setting where the longitudinal observations may
be correlated with survival, joint models of longitudinal
and survival processes have been increasingly proposed
in the past decade to recover information from these
potentially informative censorings [10-26]. Mostly, a
Gaussian mixed-effects linear sub-model is assumed for
the longitudinal response, although a t-distribution
which has a longer tail and thus is more robust to out-
liers, has been recently proposed [27], and a semi- or
fully-parametric survival sub-model fits the survival
times. Association between both longitudinal response
and survival time is modeled through a zero-mean latent
random process, and given all of the random effects,
longitudinal measurements and survival times can then
be assumed to be conditionally independent.
However, most joint models developed thus far in the
literature have focused on univariate time-to-event data,
where right censoring of the data acts independently of
the survival process under study. In contrast, in the ICU
setting, patients discharged alive are likely to be infor-
matively censored. Thus, the analysis of survival data in
the ICU in the setting of competing risks has been
recently proposed to offer significant advantages over
standard survival analyses [28,29]. Notably, they allow
taking the time dependency of risk factors and compet-
ing events into account [30].
To study the effects of a covariate in competing risk
settings, Cox analysis of cause-specific hazards has long
been the technique of choice. Thus, the joint modeling
of longitudinal and competing risk data that has been
increasingly studied for the past four years first
employed the cause-specific hazard sub-model, with a
separate latent association between longitudinal mea-
surements and each cause of failure [21,27,31-34]. How-
ever, although proportional cause-specific hazards
modelling is the standard regression model of choice to
handle competing risks, results may be difficult to inter-
pret in terms of the cumulative event probabilities.
Many authors have noted that the effect of a covariate
on the cause-specific hazard function of a particular fail-
ure type may be very different from its effect on the
cumulative incidence function [28,35-37]. For support-
ing clinical decision making, such cause-specific crude
cumulative incidence, also known as the cause-specific
subdistribution function, which is the probability of the
occurrence of a specific event of interest, is widely
recognized as clinically useful. This has led to the devel-
opment of the proportional subdistribution hazards
model [36], which offers a synthesis of single cause-spe-
cific hazards analyses.
In this paper, we propose a joint random effects
model for a longitudinal marker and competing risks
data that comprises a proportional subdistribution
hazards submodel for the competing risks failure time
data. We use the Markov chain Monte Carlo technique
of Gibbs sampling to estimate the joint posterior distri-
bution of the unknown parameters of the model, as pre-
viously proposed [14,31,38]. The paper is organized as
follows. First, the ICU data is briefly presented. The
next section describes the statistical joint model for the
longitudinal and dropout processes.
The performance of our method is evaluated and
compared with the cause-specific hazards submodel
using both simulated data and the ICU clinical trial.
Finally, a discussion is provided in the last section.
Methods
Motivating example
We analyzed data from an ongoing double-blind, paral-
lel-arm, randomized clinical trial, conducted with 1,401
critically ill patients. Since our analyses only aim at illus-
trating modeling approaches of ICU data and due to the
blind allocation of treatment arms, they will be referred
as arm A (n= 703) and arm B (n= 698) hereafter. The
median age was 63 (95%CI: 48-74) years, and 854 of the
participants (61.0%) were men. At randomization (day
0), 664 (47.4%) patients presented with sepsis and 124
(8.9%) with trauma. Main characteristics were well
balanced between randomized groups (Table 1).
All patients were followed until ICU discharge or day
28, whichever occurred first. The main endpoint was
survival within 28 days following randomization. Of the
1,401 patients admitted to the ICU, 373 (26.6%) died in
the ICU before day 28, 860 (61.4%) were discharged
alive from the ICU within the first 28 days, and 168
(12.0%) were still alive in the ICU at day 28, thus
administratively censored. Figure 1 summarizes the
competing risk setting.
During the ICU stay, the SOFA score, which was mea-
sured every day up to day 7, then on day 14 and day 28
unless the ICU discharged the patient, was used to
define a secondary endpoint of treatment effectiveness.
We were thus interested in estimating the treatment
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course over time could be considered as different in the
two randomization arms or not (Figure 2a). As depicted
by the non parametric smooth curve from trial data
[39], a linear time average trend was considered. Indeed,
the average SOFA decreases over time monotonically,
and quadratic time trends appeared unlikely though
possibly more rapidly within the first seven days. Of
note, this could be explained by the data due to the
absence of any time points after day 7 except at day 14
and day 28, with a marked decrease of information after
day 7 (as plotted in Figure 2). Thus, we decided to only
introduce a global linear time trend in the model. We
also adjusted for potential confounders, namely age
(dichotomized according to the sample median, 63
years), gender, and randomization strata (sepsis or other
presentation mode). Age was analyzed as binary, though
grouping may be seen as an extreme form of rounding
with a resulting loss of information and power to detect
real relationships [40]. However, continuous variable
would require that the true risk increases (or decreases)
monotonically with the level of the variable. Thus, we
preferred to avoid such an additional assumption and to
focus on the modeling of longitudinal response. Esti-
mated coefficients and standard errors from the longitu-
dinal model are displayed in Table 2. As expected, there
was a significant decreasing pattern of the SOFA score
over time, on average, by 0.22 points each day (95%CrI:
-0.23, -0.20). However, the significance of the interaction
term between the treatment group and time indicates
that this developing trend of SOFA for the two treat-
ment groups was different: indeed, during one day, the
SOFA decrease for one group was 0.02 (95%CrI: -0.04,
-0.003) less than that of the other group. The SOFA
score course was also affected by the patient gender -
with higher average SOFA values in males than in
females - and the randomization strata - where the
SOFA score values were on average higher in the case
of septic patients.
However, once a patient is discharged from the ICU
either alive or dead, he (she) drops out of the study, and
hence, no longitudinal measures of the SOFA scores can
be collected thereafter. This explains why some trajec-
tories from Figure 2a are shortened as compared to the
others, resulting in risk sets of exposed individuals (still
alive in ICU) that decrease as time passes (Figure 2b).
Thus, some selection bias is possibly introduced since
analyzed populations over time differ from that origin-
ally enrolled in the trial. Indeed, since SOFA scores are
time-dependant covariates that impact the outcome,
either death or discharge alive, it is likely that deaths
and discharges from the ICU should be considered as
informative dropouts of the longitudinal SOFA process.
To represent the occurrence of informative dropouts,
two main approaches have been developed in the setting
of competing risks, that differ in terms of the underlying
function of interest and thus, risk sets. The cause-speci-
fic cumulative hazard of the Cox model displays the
cumulative risk of failure from each cause of failure,
conditionally on being free of any cause of failure
(Figure 3a). Thus patients considered at risk of death in
ICU at time t are only those who were not discharged
alive before t (Figure 3c). By contrast, the subdistribu-
tion hazard could be obtained directly from the
Table 1 Main characteristics of patients according to randomized arm
N (%) Arm A (n = 703) Arm B (n = 698) p value
Age (≥63 years) 360 (51.2) 347 (49.7) 0.59
Male Gender 423 (60.2) 431 (61.7) 0.54
Inclusion strata Trauma patients 62 (8.8) 62 (8.9)
Sepsis patients 329 (46.8) 335 (48.0) 0.89
Other patients 312 (44.4) 301 (43.1)
SOFA score, median[Q1-Q3] 7.0 [5.0-7.75] 7.0 [5.0-7.74] 0.94
Figure 1 ICU data: Graphical representation of the competing
risk setting.
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Figure 2 Exploratory plots of longitudinal ICU data. Exploratory plots of longitudinal ICU data: Evolution of individual SOFA scores with non
parametric smooth curve (a) and risk sets/number of patients still alive and in the ICU (b), stratified by treatment group.
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where patients having been discharged alive before t are
considered at risk of death thereafter (Figure 3d). It is
obvious from Figures 3c and 3d that the size of the risks
set decreases more rapidly over time in the cause-speci-
fic hazard model, due to the disappearance of discharges
alive. In the model for the subdistribution hazard, the
risks sets are only affected by the occurrence of deaths
in ICU. Both approaches may interfere with the result-
ing estimates on longitudinal response. Thus, to look for
the information provided by these covariates on ICU
deaths and live ICU discharges, we fitted two competing
risks models, that of cause-specific hazards and that of
Fine and Gray [41], both incorporating the same binary
prognostic covariates. Estimates of cause-specific and
sub-distribution hazard ratios are reported in Table 3.
There was no evidence of any treatment effect on either
failure cause. Regarding the prognostic factors of ICU
death, old age was significantly selected as positively
associated with both cause-specific and sub-distribution
hazards. Indeed, elderly people had an increased death
risk in the ICU and were less likely to be discharged
alive from the ICU. Conversely, the cumulative inci-
dence of live discharges from the ICU was reduced in
the oldest patients. Otherwise, the decreased cause-spe-
cific hazard of live discharge from the ICU observed in
septic patients significantly affected the cumulative inci-
dence of ICU discharges. However, this did not translate
into any significant increase in the cumulative incidence
of ICU death in septic patients, due to their decreased
cause-specific hazard risk of death.
We questioned whether incorporating such prognostic
information on dropouts would modify estimates of cov-
ariate effects on the SOFA course as exposed above.
The joint model formulation and estimation
Our joint model consists of the two linked submodels, a
linear mixed model and a competing risks model.
Longitudinal submodel
Suppose there are n patients in the study indexed by i =
1,2,...,n.L e tYij be a measure of the j
th SOFA score for
patient i at time tij ,a n dZi denote the p-vector of
explanatory variables (including treatment arm) mea-
sured at time 0 in patient i. The longitudinal submodel
consists of a linear model with random effects:
YW t ij i ij ij =+ + +
′   01 1 Zi () (1)
where b =( b0, b1) is a parameter vector of regression
coefficients commonly referred to as fixed effects in the
model; εij ~ N(0, s
2) denotes the zero-mean Gaussian
measurement error: we assumed that εim was indepen-
dent of εis for any m ≠ s; W1i(tij) refers to the subject-
specific random effects, that is, the value at time tij of
an unobserved zero{mean Gaussian random process.
Following previous reports [33,42], random slope and
random-intercept and -slope models were considered,
namely W1(t) = U1t or W1(t) = U0 + U1t,w h e r e( U0,
U1) are zero-mean bivariate Gaussian variables.
Competing risks submodel
Let Ti denote the failure time of patient i,a n dki be the
cause of failure from two possible causes, where ki =1
denotes an ICU death and ki = 2d e n o t e sal i v ed i s -
charge from the ICU. Let Ci denote the non informative
censoring time. Let δi ={ I[Ti ≤ Ci]×ki} be the event
indicator, where δi = ki in case of failure and δi =0f o r
non-informative censoring.
The submodel (3) specifies the distribution of the
competing risks survival data. It is an extension of the
subdistribution hazard model for competing risks survi-
val data described by Fine and Gray [36]
 kd t tl i m
dt
Pr t T t dt k T t (| ) ( ; | ; ) ) ZZ =≤ < + = ≥ →0
1 (2)
in which l0,k(t) is a non specified baseline subdistribu-
tion hazard for failure type k. It appears as a model ana-
logous to the Cox model but based on subdistribution
hazards, which is also known as the hazard associated
with the crude cumulative incidence function, widely
recognized as clinically useful for supporting clinical
decision-making [43,44].
To model the correlation between different failure
types, the Fine and Gray model was thus extended by
incorporating a second zero-mean latent Gaussian pro-
cess, W
k
2
() :
  k
k
k
kk tW t t e x p W t ( | , ( )) ( ) ( ( ))
()
,
() () ZZ 20 2 2 = ′ + (3)
where   22
1
2
2 () () () (,)
k = represent the fixed effects of
Z on the two competing risks, k = 1, 2, respectively.
Submodel links
Failure times were associated with the longitudinal
response through the latent Gaussian processes W1(t),
and W
k
2
() ,t h a tw e r ea s s u m e dt ob ep r o p o r t i o n a l ,i . e . :
Table 2 Separate modeling of SOFA course
Longitudinal (Posterior mean (95% CI)
Intercept 6.14 (5.66, 6.63) *
Time -0.22 (-0.23, -0.20) *
Treatment group 0.24 (-0.16, 0.67)
Time × Treatment group -0.02 (-0.04, -0.003)*
Age ≥ 63 years 0.53 (0.11, 0.94) *
Male Gender 0.46 (0.03, 0.88) *
Septic patients 1.45 (1.03, 1.86) *
Separate modeling of SOFA course - Posterior estimates of all fixed covariate
effects in the longitudinal separate sub-model. * indicates a p-value < 0.05
based on t-tests for the individual fixed effects in the longitudinal model.
Deslandes and Chevret BMC Medical Research Methodology 2010, 10:69
http://www.biomedcentral.com/1471-2288/10/69
Page 5 of 13Wt W t
k k
21
() () () () =  , where the parameters g
(k) indicate
the level of association between the two components of
the joint model. Of note, positive values of g
(k) suggests
that positive values for associated random effects
increase the hazard of “failure”, while negative values of
g
(k) s u g g e s tt h a tt h ep o s i t i v ev a l u e sf o rt h er a n d o m
effects decrease the chance of experiencing the event of
interest. We further assumed that W1 and W
k
2
()were
independent of the measurement errors εij.A tl a s t ,t h e
longitudinal measurements and competing risks survival
times were assumed to be conditionally independent,
given the covariates and random effects.
MCMC sampling procedure
The standard likelihood approach to this problem
involves integration of the two sub-models over the dis-
tribution of random effects, which requires numerical
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Figure 3 Exploratory plots of survival competing risks ICU data. Exploratory plots of survival competing risks ICU data, either based on
cumulative cause-specific hazards stratified by treatment group (a) or cumulative incidence for discharge and death (b) stratified by treatment
group; Respective risk sets/number of patients still alive and in the ICU stratified by treatment group are displayed in figures c and d,
respectively.
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Page 6 of 13integration since the two models are not conjugate. As
an alternative, to estimate the parameters of interest, we
used the Markov-chain Monte-Carlo method of Gibbs
sampling to generate the posterior distribution of all
unknown parameters of the joint model, given only the
observed data.
Such models can be first represented by a DAG
(Directed Acyclic Graph) (figure 4), which is the graphi-
cal representation of the structural model assumptions.
The structural model specifies all observables variables
and all unobservable parameters and how these quanti-
ties are related. Model quantities are represented by
nodes in the graph: stochastic nodes for random quanti-
ties, logical nodes for functions of other parameters, and
constant nodes for fixed quantities. We used non-infor-
mative priors for all parameters. The stochastic para-
meters (b(s) are given proper but minimally informative
prior distributions, while the logical expression for pre-
cision (s(s)) allows the standard deviation of the random
effect distribution to be estimated. The fixed regression
coefficients b1 and b2 were assigned a vague Gaussian
prior. The initial values of the parameters for sampling
were obtained by modeling the longitudinal data and
survival data separately. The method involves iteratively
sampling over a large number of cycles from the full
conditional distributions of each parameter given the
current assignment of all other parameters and data.
After discarding the early samples to allow the process
to converge, we used subsequent realizations of each
parameter for summarizing the posterior distribution.
We used the posterior means and variances of the
Gibbs samples to describe the results and used the 2:5
th
and 97:5
th percentiles of the empirical distributions to
estimate the 95-percent credible intervals (95%CrI). To
assess convergence, we used the guidelines proposed by
Spiegelhalter [45]. In the analyses, the results were
based on three parallel MCMC sampling chains of
30,000 iterations each, after a burn-in of 1,000 iterations.
From model alternatives of linked structures, we choose
the most parsimonious model according to the Deviance
Information Criterion (DIC) [46]. Joint models were
fitted through the use of the WinBUGS package [45]
and the R package ‘BRugs’. Separate models were fitted
using standard statistical packages (R package cmprsk
Table 3 Posterior mean hazard ratio estimates from separate survival models for competing risk data
Cause specific hazards Subdistribution hazards
ICU DEATHS No deaths/No pts HR 95%CI SHR 95%CI
Treatment group
A 191/703 1 1
B 182/698 1.04 (0.85,1.27) 1.03 (0.85,1.26)
Age
<63 years 151/717 1 1
≥63 years 222/684 1.40 (1.14,1.73)* 1.58 (1.28,1.94)*
Gender
Female 150/547 1 1
Male 223/854 0.90 (0.73,1.10) 0.95 (0.78,1.16)
Entry mode
Other 185/737 1 1
Sepsis 188/664 0.95 (0.77,1.16) 1.09 (0.89,1.33)
DISCHARGE ALIVE No events/No pts
Treatment group
A 429/698 1 1
B 431/703 0.99 (0.87,1.13) 1.00 0.87,1.14)
Age
<63 years 493/717 1 1 (0.59,0.77)*
≥63 years Gender 367/684 0.71 (0.62,0.81)* 0.67
Female 330/547 1 1
Male 530/854 0.92 (0.80,1.06) 0.95 (0.83,1.09)
Entry mode
Other 486/737 1 1
Sepsis 374/664 0.72 (0.63,0.83)* 0.76 (0.67,0.87)*
Posterior mean hazard ratio estimates from separate survival models for competing risk data, namely, the cause-specific hazard (HR) model and the sub-
distribution hazard (SHR) model. * indicates a p-value < 0.05 based on Wald tests.
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Page 7 of 13with ‘cuminc’ function for cumulative incidences, the R
package nlme for longitudinal analyses, and WinBUGs)
though other statistical packages such as SAS (SAS Inc.,
Cary, NC) could have been used [47].
Results and discussion
Application revisited
Table 4 displays posterior summary statistics for the
regression coefficients related to the SOFA score course
together with the dropout processes. Regardless of the
survival sub-model used for competing risks, the best
fitted model links the sub-models through a linear com-
bination of random effects; that is, we use the intercept-
and slope- random effect model W1 = U0 + U1t (based
on the DIC value). The marginal assumption of normal-
ity of random effects appeared to hold reasonably, on
the basis of the residual plots (data not shown). Expect-
edly, a negative association between the two model
components was observed regardless of the competing
risk sub-model, with g
(1) estimated at about 3 and g
(2) at
about -3. Indeed, this could have been anticipated, since
deaths are more likely to occur in patients with high
SOFA values, whereas patients with high SOFA scores
a r el e s sl i k e l yt ob ed i s c h a r g e da l i v ef r o mt h eI C U .P r e -
vious estimated treatment effects on the mean SOFA
course and dropouts were affected by the model assum-
ing ICU deaths and live discharges from the ICU as
informative censoring observations. Besides the prognos-
tic value on the SOFA score of gender, age and sepsis,
which remained regardless of the joint model used, the
treatment effect on either outcome was interestingly
modified by incorporating a correlation between the
SOFA course and dropouts. The modeling of the drop-
out process using cause-specific hazards erased the time
by treatment interaction on the SOFA course, while that
based on sub-distribution hazards did not. However,
interestingly, estimated treatment effect on the hazards
of death increased whatever the survival sub-model,
either for cause-specific or sub-distribution hazards, but
only reached statistical significance with the later. Simi-
larly, in the survival sub-models, the separate and joint
analyses produced differences in estimates for other
parameters such as male gender and sepsis. Actually, all
these differences between the separate and joint analyses
might be explained by the negative significance for the
covariance between the latent variable of the longitudi-
nal model and that of the survival model.
A Simulation study
Sampling details
In this section, we conducted a simulation study to illus-
trate the method, to examine the feasibility as well as
properties of the proposed joint model. We simulated
the complete data from the following intercept- and
slope- random model.
Longitudinal data were generated for n subjects from
the Gaussian linear model as given by (4). The change
in the subject’s longitudinal biomarker over time is
described using a linear mixed-effects model in which
the subject-specific effects are captured by latent vari-
ables. We consider binary covariate, continuous covari-
ate (time covariate), and an interaction between binary
Figure 4 Winbugs simplified Directed Acyclic Graph (DAG) for the joint model.
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Page 8 of 13and time covariate along with the usual intercept term.
Thus, a random intercept-and-slope model is adopted,
such that W1(t)=U0 + U1t:
YY t t
XX t W t j
ij i ij ij
i i ij i i ij
== + +
+++
()
()

 
10 11
12 13 1
(4)
where tij = 0, 1,....,7, 14, 28 represent the visit sched-
uled times, Xi Bernoulli(0:5) acts as the treatment indi-
cator in a randomized clinical trial. The random
intercept U0i and slope U1i were assumed normally dis-
tributed as N(0, sU0 )a n dN(0, sU1 ), respectively, and
independent of the measurement error εij~N(0, 0.1).
Estimates from separate analysis of the longitudinal and
the time to event components were reasonable starting
values for the model.
For simplicity, we considered only two competing
risks (k = 2), with failure times data generated through
the method described by Fine and Gray [41] but includ-
ing frailty. Distinct baseline hazards were used for each
risk, and the same binary covariate as used in the longi-
tudinal sub-model was incorporated into the competing-
risks sub-models. Briefly, the sub-distribution for the
failures of interest are given by:
Pr T t k X W
pe x p t
ii
XW i
(;; , )
[ ( ( ))]
()
exp( (
() ()
≤= =
−− − −
+
1
11 1
2
1
2
1
2
1  t t))
(5)
which is a unit exponential mixture with mass 1 - p
at ∞ when X = 0, and uses the proportional subdistribu-
tion hazards model to obtain the subdistribution
for nonzero covariate values. The subdistribution for
the competing risks failure cause was then obtained
using an exponential distribution with rate exp
(( ) )
() () 2
2
2
2 XWt i + . As detailed above, proportional
association between the longitudinal data and the com-
peting risks was generated by setting
WtW t
k
21
() () () =×  .
Censoring times were generated from an exponential
distribution with rate 0.25. We used the true parameter
value of p = 0.25, for n = 100, 500 subjects. This gave
25 per cent cause 1 failures, 65 per cent cause 2 failures,
and 10 per cent of censoring.
Based on the collection of previous analyses illustrated
in Tables 2 and 3, the following proper priors were used
Table 4 Posterior estimates for the ICU data based on joint models
Modeling of dropouts Cause specific hazards Subdistribution hazards
Sub-model
LONGITUDINAL Posterior mean (95% CrI)) Posterior mean (95% CrI))
Intercept 6.29 (6.05, 6.53)* 6.24 (5.74, 6.75)*
Time -0.05 (-0.07, -0.04)* -0.06 (-0.07, -0.05)*
Treatment group 0.34 (0.10, 0.58)* 0.26 (-0.17, 0.68)
Time × Treatment group -0.012 (-0.04, 0.01) -0.02 (-0.03, -0.003)*
Age (years) 0.45 (0.27, 0.63)* 0.53 (0.12, 0.96)*
Male Gender 0.44 (0.25, 0.63)* 0.47 (0.02, 0.96)*
Septic patients 1.33 (1.15, 1.51)* 1.44 (1.01, 1.86)*
SURVIVAL HR (95% CrI)) SHR (95% CrI))
DEATHS
Treatment group 1.22 (0.98, 1.53) 1.23 (1.00, 1.53)*
Age (years) 1.93 (1.55, 2.41)* 1.38 (1.10, 1.74)*
Male Gender 1.19 (0.96, 1.50) 1.35 (1.07, 1.69)*
Septic patients 1.38 (1.11, 1.72)* 1.18 (0.95, 1.46)
g
(1) 3.32 (3.09, 3.57) 3.42 (3.24, 3.61)
DISCHARGES
Treatment group 1.17 (1.02, 1.36)* 1.25 (1.08, 1.43)*
Age (years) 0.91 (0.79, 1.05) 1.08 (0.93, 1.24)
Male Gender 1.25 (1.07, 1.45)* 1.30 (1.11, 1.51)*
Septic patients 1.02 (0.88, 1.18) 1.12 (0.96, 1.29)
g
(2) -2.96 (-3.11, -2.80) -3.35 (3.48, -3.22)
The upper table displays longitudinal joint estimates, and the lower table displays the survival estimates in cause-specific hazards and sub-distribution hazards. *
indicates statistically significance at level 0.05 (in the Bayesian sense; 95% credible set excludes 0)
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() k . The method used informa-
tive priors for some parameters with the prior means (b’s)
set as the true parameter values. Setting g =1i n d u c e sa
positive association between the competing risks. We also
set g = -1 to induce negatively associated competing risks,
that may apply when discharge is a competing cause of
failure, as observed in the motivating exemple. Longitudi-
nal responses were missing after the observed or censored
event times, with an averaged number of total longitudinal
observations of 7:0 per subject. This is consistent with the
example findings (6:6 observations per subject). After a
burn-in phase of 1,000 iterations, eliminated from the
sample to avoid influence of initial parameters, we used
means and standard deviations of a single series of 10,000
Gibbs samples as point estimates of the parameters and
their standard errors. A total of 100 simulations were per-
formed. Simulations were carried out in R language (R
Development Core Team) [48].
Simulation results
Estimated bias and standard deviations (SD) of the pos-
terior means are reported in Table 5. First of all, the
intercept b10 and time trend b11 of the longitudinal
measurements were overestimated when the sample size
is not that large (n = 100). Our results are consistent
with the findings of Elashoff et al. [21], who reported
that biases and/or variances for these parameters were
larger for the joint model than the separate. However,
smaller biases and variances could be observed with lar-
ger sample sizes, and we are able to obtain almost
unbiased estimates for all the quantities in the joint ana-
lysis based on 500 subjects. Accurate estimation of the
association parameters g was obtained. At last, we note
that the joint model could be conservative in the sense
that the estimated standard errors tend to be slightly
larger than the true ones.
Discussion
In this paper, we aimed at comparing two treatment
groups with respect to the course of the SOFA score in
critically ill patients. Analysis was complicated by infor-
mative dropouts, since once a patient has been dis-
charged, either alive or dead, from the ICU, no
Table 5 Simulation study
Positive association Negative association
Parameter True value Bias (SD) True value Bias (SD)
n = 100
Longitudinal
Intercept b10 6.15 0.24 (0.16) 6.15 0.20 (0.16)
Time b11 -0.25 0.22 (0.03) -0.25 0.19 (0.04)
Binary covariate b12 0.25 0.01 (0.19) 0.25 0.01 (0.20)
Interaction Time × Binary covariate b13 0.0 -0.03 (0.03) 0.0 -0.05 (0.03)
Survival
Binary covariate b2 0.0 0.25 (0.34) 0.0 0.39 (0.35)
g 1.0 -0.09 (0.12) -1.0 0.13 (0.12)
Variances
sU0 1.0 0.04 (0.14) 1.0 0.02 (0.13)
sU1 1.0 0.02 (0.13) 1.0 0.02 (0.13)
n = 500
Longitudinal
Intercept b10 6.15 0.20 (0.16) 6.15 0.23 (0.04)
Time b11 -0.25 0.02 (0.02) -0.25 0.05 (0.05)
Binary covariate b12 0.25 0.04 (0.22) 0.25 0.03 (0.06)
Interaction Time × Binary covariate b13 0.0 -0.007 (0.04) 0.0 -0.01 (0.01)
Survival
Binary covariate b2 0.0 0.12 (0.29) 0.0 -0.16 (0.12)
g 1.0 -0.03 (0.09) -1.0 -0.04 (0.10)
Variances
sU0 1.0 0.02 (0.14) 1.0 0.04 (0.12)
sU1 1.0 0.03 (0.14) 1.0 0.03 (0.13)
Simulation study, bias and standard deviations (SD) estimates of the posterior means for competing risk joint model, sample size = 100, 500.
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Page 10 of 13longitudinal measure of the severity score of interest can
be collected thereafter. Thus, when analyzing such data,
separate modeling of the SOFA score, that is, ignoring
the dropout process, is likely to be inappropriate and
one should obtain less biased and more efficient infer-
ences using joint models Actually, joint models allow
incorporating informative censoring and time by treat-
ment interaction, and provide complementary informa-
tion when assessing how the treatment manifests itself
through the marker [49].
Such joint models in this particular setting required
modelling assumptions. First, to assess time by treat-
ment interaction on the SOFA score, a linear time effect
was assumed. Indeed, as depicted in Figure 2a, the aver-
age SOFA monotonically decreases over time, so that
quadratic time pattern was unlikely. Of note, the
observed profiles may have suggested a change point at
7 days in the slope whatever the treatment arm, so that
a piecewise mixed-effects model could have been fitted.
However, we only introduced one linear time trend
because of the data, due to the absence of any time
points after day 7 except at day 14 and day 28, and due
to the increased amount of informative dropouts over
time, notably after day 7 (Figure 2b). Secondly, in the
particular setting of ICU data, where dropouts result
from either deaths or live discharges, models for com-
p e t i n gr i s kf a i l u r et i m ed a t as h o u l db eu s e dt of i tt h e
survival responses [28-30]. Since the SOFA score was
actually measured only in patients during their ICU
stay, the possibly informative dropout process of interest
was clearly that of ICU deaths/discharges. This avoided
open issues with regards to the primary outcome to be
used in the ICU, as well as on the model to be fitted to
such data -either based on binary [50] or survival data
analysis techniques [30]. Joint models could also apply
to other competing risks settings such as those pub-
lished by the UCLA team in scleroderma-related inter-
stitial lung disease with intermittent measures of forced
vital capacity which were informatively censored by
study withdrawal due to disease or treatment related
reasons [27,32,51]. Based on our simulation study, we
observed that an increase in the sample size decreased
the estimation bias for the parameters in both submo-
dels. However, we observed, as also noted by Hu [38] in
their own model, that the implemented method is sensi-
tive to outliers. A further development will be to imple-
ment a more robust joint model for longitudinal and
survival data.
A few authors have already proposed a joint modeling of
longitudinal and multivariate survival data [31,33,38]. Our
proposed approach differs from those in two main points.
First, a cause-specific hazard sub-model [33] or a frailty
model [31] has been conventionally used to handle several
types of failures; we decided instead to fit to a sub-
distribution hazard sub-model [36] to provide estimates of
treatment effect directly related to the cumulative inci-
dence of dropouts [43,44]. Secondly, an EM algorithm was
used for inference purposes in [33]. Actually, the Bayesian
framework of Chi in 2006 [31] motivated our investigation
of a Bayesian alternative that allows full and exact poster-
ior inference for any parameter or predictive quantity of
interest. Thus, we developed a fully Bayesian approach,
implemented via MCMC methods using WinBUGS soft-
ware, as previously reported [14,31,52,53]. Such a Bayesian
method for joint modeling of longitudinal and competing
risks survival data was very recently reported in the setting
of cause-specific hazards sub-model [38]. We illustrated in
this paper how the joint model strategy may affect the
results. Our results suggest that the treatment effect on
the SOFA course in separate modeling of the SOFA
course could be evidenced when considering informative
censoring modeled by sub-distribution hazards. The sig-
nificant treatment by time interaction was erased by the
modeling of informative dropouts throughout cause-speci-
fic hazards.
In the setting of joint modeling of competing risks
together with that of longitudinal response, such a differ-
ence in the handling of competing risk outcomes based on
the Fine and Gray model appears to translate into the
observed difference in treatment effect on the longitudinal
outcome. This makes clear the requirement for statistical
analysis of such data to be clearly planned in the protocol
of such studies. Other approaches, such as marginal struc-
tural models for non-dynamic treatment regimes, appear
to be of prime interest in this setting [54,55].
Valid inference requires a framework in which poten-
tial underlying relationships between the event and
longitudinal process are explicitly acknowledged. Latent
variable models used in this context do not directly
model the association between longitudinal and survival
response, but rather focus on correlated, latent random
effects. The random intercept-and-slope model was
found to give a significantly improved fit (by DIC) above
other models examined such as the random intercept-
only model. This is similar to that reported by William-
son [33]. Additionally, Henderson et al. [15] described a
latent variable association model, and Lin et al. [56]
concentrated on latent class mixed models. In a recent
paper, Liu [57] showed that the hazard of death may be
dependent on random effects from various levels. In this
way, Tsiatis and Davidian provided a nice overview of
joint models [12], describing further details on underly-
ing assumptions statements and on the likelihood of
model parameters in such models.
Conclusions
The consideration of joint models permits useful analy-
sis of very complex data. It could help to improve
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Page 11 of 13estimation of the impact of proposed prognostic features
o nt h em a i ne n d p o i n t si nt h et r i a l .W ep r o p o s e da
method that gives accurate estimates, and a Bayesian
alternative that permits full and exact posterior infer-
ence for any parameter or predictive quantity of interest.
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